Remepy Prepares Phase 3 Trial of Hybridopa for Parkinson’s Disease

According to a recent LinkedIn post from Remepy, the company plans to participate in the upcoming World Parkinson Congress in Phoenix, where researchers, clinicians, patients, and care partners convene. The post indicates that Remepy intends to present three posters from its Parkinson’s research program and engage directly with clinicians and advocates.

The company’s LinkedIn post also suggests that Remepy is preparing to initiate a Phase 3 trial of Hybridopa, its investigational hybrid drug candidate for Parkinson’s disease, in the second half of 2026. For investors, the move toward a late-stage clinical trial may signal a maturing pipeline asset and a potential future value inflection point, while participation at a major disease-specific forum could help build clinical relationships and stakeholder awareness in a competitive neurodegenerative therapeutics landscape.